Insect biotech as India's next deeptech opportunity: Ankit Alok Bagaria, Co-founder and CEO, Loopworm

We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms

Europe Treponema pallidum tests market to grow at 3% CAGR through 2036

Increasing syphilis cases, stronger STI surveillance initiatives, and growing emphasis on early diagnosis are expected to support sustained demand

Glenmark posts strong FY26 results with 27.5% revenue jump

FDA delays AstraZeneca decision on camizestrant as regulators seek more data

The filing is backed by results from the pivotal SERENA-6 Phase III trial

Fermenta Biotech reports 26% revenue growth in FY26

Lupin's novel cancer therapy LNP8701 shows encouraging results in phase 1 trial

First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors

India’s MedTech industry is entering its defining decade: Dr. Shravan Subramanyam, MD, BPL Medical Technologies

From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies

Hikal swings back to profit in Q4 FY26 despite regulatory hit & strategic charges

Hikal’s Q4 profit remained sharply lower year-on-year, falling 71% from Rs. 50.2 crore in Q4 FY25 as the company absorbed regulatory pressures and strategic accounting adjustments

Gandhar Oil posts robust FY26 profit

PAT soars 201%, EBITDA up 88% on strong PHPO demand & margin expansion

Morepen Labs posts strong Q4 FY26 net profit

For the full year, standalone gross revenue crossed Rs. 1,700 crore